Topics

Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

11:58 EDT 13 Sep 2019 | BioPortfolio Reports

Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 Pipeline Review, H1 2019


Summary


Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Inhibition of receptor acts as a major negative regulator of Tcell responses.


Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 pipeline Target constitutes close to 56 molecules. Out of which approximately 55 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 7, 15, 2, 22 and 6 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.


Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Solid Tumor, Melanoma, NonSmall Cell Lung Cancer, Metastatic Melanoma, Metastatic Breast Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Cervical Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma, SmallCell Lung Cancer, Colon Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Anal Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Metastatic Transitional Urothelial Tract Cancer, Muscle Invasive Bladder Cancer MIBC, Nasopharyngeal Cancer, NonHodgkin Lymphoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Anaplastic Thyroid Cancer, Esophageal Cancer, Gastroesophageal GE Junction Carcinomas, Germ Cell Tumors, Hematological Tumor, Lymphoma, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Pancreatic Cancer, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, Osteosarcoma, Prostate Cancer, Salivary Gland Cancer, Vaginal Cancer, Vulvar Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenoid Cystic Carcinoma ACC, Adrenal Gland Cancer, Adrenocortical Carcinoma Adrenal Cortex Cancer, Advanced Malignancy, Basal Cell Carcinoma Basal Cell Epithelioma, Bile Duct Cancer Cholangiocarcinoma, Chronic Lymphocytic Leukemia CLL, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Dedifferentiated Liposarcoma, Diffuse Large BCell Lymphoma, Dysgerminoma, Ependymoma, EpsteinBarr Virus HHV4 Infections, Ewing Sarcoma, Follicular Thyroid Cancer, Gallbladder Cancer, Germinomatous Seminomatous Germ Cell Tumors, Glioblastoma Multiforme GBM, Gliosarcoma, Graft Versus Host Disease GVHD, Head And Neck Cancer, HighGrade Glioma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, HormoneSensitive Prostate Cancer, Kaposi Sarcoma, Leukemias, Liver Cancer, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, NonSmall Cell Lung Carcinoma, Nongerminomatous Nonseminomatous Germ Cell Tumors, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor PNET, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Transitional Cell Cancer Urothelial Cell Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ureter Cancer, Urethral Cancer, Urinary Tract Cancer and Uveal Melanoma.


The latest report Cytotoxic T Lymphocyte Protein 4 Pipeline Review, H1 2019, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics development with respective active and dormant or discontinued projects.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4

The report reviews Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics and enlists all their major and minor projects

The report assesses Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Cytotoxic T Lymphocyte Protein 4 Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...